Bleeding
Bleeding
Title:
Purpose: To evaluate the safety and efficacy of Beriplex® P/N so that it can be licensed and sold in the United States. The study is
designed to show that Beriplex® P/N is at least as effective as (or no worse than) human plasma in returning thinned blood
towards normal.
Eligibility Male and female patients in the ICU at Sinai Hospital of Baltimore, 18 years of age or older who have received oral vitamin
K-antagonist therapy and have acute major bleeding.
Principal Investigator: Rubenfeld, Joshua
Phase: III
For more information, contact: Highfield, David
Telephone Number:
Email dhighfield@
Approved Enrollment Number: 6
Current Enrollment: 0
Cardiovascular Disease
Title:
Purpose: To determine the safety and efficacy of the Absolute Pro Peripheral Self-Expanding Stent System (Absolute Pro stent) and
the Omnilink Elite Peripheral Balloon-Expandable Stent System (Omnilink Elilte stent) in subjects with atherosclerotic de
novo or restenotic lesions in the native common iliac artery and/or native external iliac artery.
Eligibility Subject must be at least 18 and less than 90 years of age, and have had a history of symptomatic claudication (Rutherford
Becker Clinical Category 2-3) or ischemic rest pain (Rutherford Becker Clinical Category 4).
Principal Investigator: Prewitt, Kerry C.
Phase: III
For more information, contact: Dudek, Audrey
Telephone Number: 410-583-1170
Email adudek@
Approved Enrollment Number: 10
Current Enrollment: 0
Cardiovascular Disease
Title:
Purpose: To identify the optimal duration of dual antiplatelet therapy in subjects who undergo stenting procedures.
Eligibility Study subjects with ischemic heart disease due to stenotic lesions in either native coronary arteries or coronary artery bypass
grafts undergoing PCI with stent placement and no contraindications to prolonged DAPT are eligible to be enrolled in this
study. Subjects may have multi-vessel treatment.
Principal Investigator: Gurbel, Paul A.
Phase: IV
For more information, contact: Bliden, Kevin
Telephone Number: 410-601-4795
Email kbliden@
Approved Enrollment Number: 50
Current Enrollment: 0
Cardiovascular Disease
Title:
Purpose: To provide evidence that point-of-care genetic and platelet function testing can be successfully used to identify patients at
ischemic risk and alter therapy using an algorithm to guide clinicians in the management of antiplatelet therapy.
Eligibility Subjects, 18 years of age or older, who have ischemic heart disease due to stenotic lesions in either native coronary arteries or
coronary artery bypass and undergo PCI with stent placement and have no contraindication to prolonged dual antiplatelet
therapy (=1 year) are eligible to be in the study.
Principal Investigator: Gurbel, Paul A.
Phase: III
For more information, contact: Bliden, Kevin
Telephone Number: 410-601-4795
Email kbliden@
Approved Enrollment Number: 1500
Current Enrollment: 0
Carotid Artery Disease
Title:
Purpose: To collect data about patients' medical experiences and conditions following treatment of carotid stenosis using one of Abbot
Vascular's carotid stent systems and embolic protection systems.
Eligibility Anyone that has a blockage of the carotid artery and is considered at high risk for carotid endarterectomy surgery.
Principal Investigator: Mastali, Kourosh
Phase: IV
For more information, contact: Dudek, Audrey
Telephone Number: 410-583-1170
Email adudek@
Approved Enrollment Number: 50
Current Enrollment: 0
Coronary Heart Disease
Title:
Purpose: To evaluate the safety and efficacy of the REG1 Anticoagulation System in ACS patients undergoing cardiac catheterization
by determination of the clinically acceptable dose range of RB007, which can be used to reverse the anticoagulant effect of
RB006.
Eligibility Male or female subject, 18 - 85 years of age (inclusive) who are admitted for Acute Coronary Syndrome at Sinai Hospital's
Heart Center to undergo cardiac catheterization.
Principal Investigator: Gurbel, Paul A.
Phase: II
For more information, contact: Bliden, Kevin
Telephone Number: 410-601-4795
Email kbliden@
Approved Enrollment Number: 25
Current Enrollment: 0
Coronary Heart Disease
Title:
Purpose: To evaluate the effect of dalcetrapib treatment for 2 years on atherosclerotic disease progression - as assessed by coronary
intravascular ultrasound (IVUS) and carotid B-mode ultrasound - in patients with coronary artery disease (CAD).
Eligibility Male and female patients over 18 years of age scheduled for clinically indicated coronary angiography and possible ad hoc
percutaneous coronary intervention (PCI). Evidence-based management of LDL-C cholesterol, at a minimum to include
medical and dietary treatment to a target level of ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- bleeding after myomectomy what s normal
- light bleeding with yeast infection
- traumatic intracranial bleeding icd 10
- risk of bleeding icd 10
- icd 10 rectal bleeding unspecified
- bleeding from tracheostomy icd 10
- abnormal uterine bleeding icd 10
- gum bleeding icd 10
- oral bleeding icd 10
- icd 10 code for bleeding gums
- easy bleeding icd 10
- bleeding icd 10 code